HCW Biologics (HCWB) Cash from Financing Activities (2020 - 2025)

HCW Biologics (HCWB) has 6 years of Cash from Financing Activities data on file, last reported at $4.2 million in Q4 2025.

• Quarterly Cash from Financing Activities fell 36.43% year-over-year to $4.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $10.7 million (down 31.47% YoY) and the FY2025 annual result came in at $10.7 million, down 31.47% from the prior year.
• Cash from Financing Activities advanced to $4.2 million in Q4 2025, from $1.9 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $98.5 million in Q4 2021 to a low of -$48.4 million in Q3 2021.
• A 5-year average of $4.1 million and a median of $6856.0 in 2022 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2021 — Cash from Financing Activities plunged 883.93% — and 2024, when it surged 222022.78%.
• Tracing HCWB's Cash from Financing Activities over 5 years: stood at $98.5 million in 2021, then sank by 100.04% to -$39846.0 in 2022, then jumped by 61.73% to -$15250.0 in 2023, then jumped by 43540.29% to $6.6 million in 2024, then slumped by 36.43% to $4.2 million in 2025.
• The last three Cash from Financing Activities figures came in at $4.2 million (Q4 2025), $1.9 million (Q3 2025), and $4.6 million (Q2 2025), per Business Quant data.